Material Event (Form 8-K)

Item 8.01 Other Events.

On August 7, 2026, BioRestorative Therapies, Inc. (the "Company") suspended, effective immediately, all orders and shipments of its biocosmeceutical product lines, consisting of its ExoCR products and its BioX products, pending a business review and regulatory assessment. The Company has not made a decision to discontinue these product lines.

The Company is conducting a review of the documentation, sourcing, and regulatory status associated with these products.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the Company's business review and regulatory assessment, the potential outcomes of that review, and the status of the Company's biocosmeceutical product lines. These statements are based on the Company's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including the outcome of the review, the Company's ability to resume sales of the affected product lines, the costs associated with the suspension, the Company's need for additional capital, and the risk factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 and its subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement except as required by law.